Editorial

A clinical care pathway for von Hippel–Lindau management has been developed by von Hippel–Lindau experts and patients. In this retrospective cohort study, 65 women with PTEN Hamartoma Tumor Syndrome (PHTS) were included, of which 39 were enrolled in the breast cancer (BC) surveillance program and underwent annual breast magnetic resonance imaging and mammography. Performance measures of BC surveillance were adequate, the cancer detection rate was high (45/1000 rounds), and BCs detected during surveillance were more often early stage compared with BCs detected outside surveillance. BC surveillance in women with PHTS is effective because it contributes to the detection of early-stage BCs. 2 show that phase 3 trials comparing adjuvant therapies to observation are at risk for informative censoring that could potentially impact interpretation of study results. according to the most relevant prognostic features could better defi ne the biological behavior of the disease and thus allow better tailoring of adjuvant treatment. Human papillomavirus (HPV)-positive nasopharyngeal carcinoma (NPC) and Epstein–Barr virus (EBV)-positive NPC seem to be mutually exclusive diseases, and p16/HPV testing is helpful in EBV-negative NPC to elucidate potential viral etiology. HPV-positive NPC presents with a greater local symptom burden compared with EBV-positive NPC and HPV-positive oropharyngeal carcinoma, but outcomes are similar. Presence of TP53 mutations in acute myeloid leukemia (AML) are associated with an inferior outcome after an allogeneic stem cell transplant. This data demonstrates inferior overall survival post allograft in TP53 mutant AML is seen only in the presence of chromosome 17p loss or complex karyotype. In the absence of prospective data, this retrospective analysis of fi rst-line cytotoxic chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma (WDLPS) confi rms marginal activity of anthracycline monotherapy (overall response rate [ORR], 6%; median progression-free survival [m-PFS], 4 months), whereas doxorubicin-ifosfamide appeared more active (but not statistically signifi cant; ORR, 22%; m-PFS, 12 months). This retrospective study provides a benchmark for future trials on new drugs in WDLPS. conduct the Linxian Dysplasia Nutrition Intervention Trial. The purpose of this report is to update the results of this randomized, double-blind, placebo-controlled trial after nearly 35 years of follow-up and provide evidence for the effect of multivitamin supplementation on health. This report is the fi rst clinical trial to describe the use of a poly(ADP-ribose) polymerase inhibitor as monotherapy in children. Olaparib was well tolerated, with preliminary antitumor responses observed in DNA damage response–defective pediatric tumors. The authors present results from a validation study of an innovative pharmacogenomic tool to predict effective chemotherapeutic drug therapy for patients with advanced pancreatic cancer based on profi ling of circulating tumor and invasive cells isolated from peripheral blood. Results show that a simple blood test can guide an individualized approach to treating pancreatic cancer, leading to improved survival across the two standard frontline chemotherapy regimens. Although high-risk neuroblastoma patients with poor end-induction response are commonly treated with bridge therapy before consolidation with autologous stem cell transplantation (ASCT), the effi cacy of this approach has not been evaluated. In this retrospective, multi-institutional study, patients with end-induction stable disease at metastatic sites who received bridge therapy had signifi cantly improved event-free survival (EFS) in comparison with those who directly underwent ASCT, and patients with a complete metastatic response after post-induction therapy who did not undergo ASCT had signifi cantly better 3-year EFS in comparison with those with residual metastatic disease.